Lyra Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Lyra Therapeutics

08/11/2022 22:01

* Lyra Therapeutics Inc  LYRA.OQ  reported a quarterly
adjusted
loss of 40 cents​​ per share for the quarter ended in September.
The mean expectation of five analysts for the quarter was for a
loss of 44 cents per share.
    * Revenue rose 2,464.3% to $359.00 thousand from a year ago;
analysts expected $135.67 thousand. 
    * Lyra Therapeutics Inc's reported EPS for the quarter was a
loss
of 40 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Lyra Therapeutics Inc shares had fallen by 7.4% this
quarter and
gained 6.4% so far this year.
    * The company reported a quarterly loss of $14.77 million.
    * Wall Street's median 12-month price target for Lyra
Therapeutics
Inc is $16.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 10:01 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.44          -0.40          Beat
 Jun. 30 2022      -0.37          -0.43          Missed
 Mar. 31 2022      -0.91          -0.54          Beat
 Dec. 31 2021      -0.79          -1.05          Missed